Human I-TAC ELISA Kit ELH-ITAC from RayBiotech | Biocompare.com

Supplier Images

Image URL

Be the first to write a review!

Citations:

Supplier Page from
RayBiotech for
Human I-TAC ELISA Kit

Description

RayBio® Human I-TAC (CXCL11) ELISA Kit for cell culture supernatants, plasma, and serum samples. Lead time: Typically ships within 1-2 business days. No Friday shipments

Product Specs
ItemHuman I-TAC ELISA Kit
CompanyRayBiotech
Price $469.00Supplier Page View Company Product Page
Catalog NumberELH-ITAC
ReactivityHuman
Detection TargetI-TAC (CXCL11)
Quantity1 Plate Kit, 2 Plate Kit, 5 Plate Kit
NCBI Full Gene NameC-X-C motif chemokine ligand 11
NCBI Gene AliasesSCYB9B, SCYB11, b-R1, I-TAC, H174, IP-9, IP9
ApplicationsSandwich ELISA
Sample TypeCell Culture Supernatants, Plasma, Serum
Sensitivity2 pg/ml
Detection Range2 pg/ml - 600 pg/ml
Research AreaChemokine Biology, Inflammation

Add to Compare List

RayBiotech

RayBiotech

3607 Parkway Lane, Ste. 200

Peachtree Corners, Georgia 30092

United States

Phone: 770-729-2992
888-494-8555

Company Profile

Website: www.RayBiotech.com

(1) Angiotensin converting enzyme 2 gene expression and markers of oxidative stress are correlated with disease severity in patients with COVID-19Molecular biology reportsJuly 1, 2023Alobaidy ASH, Elhelaly M, Amer ME, Shemies RS, Othman AI, El-Missiry MA.

(2) Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung CancerAnticancer researchDecember 1, 2015Spaks A, Jaunalksne I, Spaka I, Chudasama D, Pirtnieks A, Krievins D.

(3) Resveratrol attenuates CXCL11 expression induced by proinflammatory cytokines in retinal pigment epithelial cellsCytokineAugust 1, 2015Kutty RK, Samuel W, Abay R, Cherukuri A, Nagineni CN, Duncan T, Jaworski C, Vijayasarathy C, Redmond TM.

(4) IL-27 inhibits lymphatic endothelial cell proliferation by STAT1-regulated gene expressionMicrocirculation (New York, N.Y. : 1994)August 1, 2013Nielsen SR, Hammer T, Gibson J, Pepper MS, Nisato RE, Dissing S, Tritsaris K.

(5) Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effectsOncotargetDecember 1, 2011Yi T, Elson P, Mitsuhashi M, Jacobs B, Hollovary E, Budd TG, Spiro T, Triozzi P, Borden EC.

Be the First to Write a Review!